focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
excellent news, hopefully a nice rise. Only wish that SAR had some news like this!!
L, i guess because the small £ that PYC can demand from companies like Bicycle, its cheaper for Bicycle & Merck for that matter to use us on a yearly basis rather than buying us. tbh
Thanks Ralph
In response to your tweet message, it was a rollover.
What is Rollover? A rollover means carrying forward your future positions from closing your positions near the expiry date to opening the same new position in a further-out month contract. In simpler words, the process of carrying forward your position from one month to another month is called a rollover.
since when has this company had 3+ years cash runway and is near to profit??
this has gone sour poor show
It was interesting from Kidlingtons Post at the weekend that Bicycle were now mentioning project optimus from Nov 2022, also they had £350mln in Cash
Silly question but if Bicycle are going to keep spending money with us why don't they just buy PYC ?
What do more knowledgeable posters think ?
How is todays RNS having a material effect on the co ? What a total waste of money !!!!!!! Everyone already knew !! What are the brokers here doing ????
Could soon have a Rns here of worth re.Val works after a fabulous presentation by val ceo Suzy Dilly last night which strongly alluded to completion of 201 deal and funding ‘soon’ .Would mean serious cash payment to a company with a Mcap of just over 2 mill.Before Crimbo is the general consensus.
Yep, as predicted a RNS about the conference which we knew about 2 weeks ago.
A blatant waste of money? They'd already to,d us on twitter about it.
Guess we get a RNS saying they are sponsoring hub xchange at in a few weeks time?
only good thing was to see https://jitc.bmj.com/content/10/Suppl_2/A1341 i;d like to copy/paste the conclusion, but not sure about the copyright implications?
Annual Meeting of the Society for Immunotherapy of Cancer ("SITC"), being held this week on 8-12 November 2022 in Boston, USA.
The Company will be presenting an original poster entitled: "Establishing the preclinical PKPD relationship for NM32-2668 a ROR1 targeting T cell engager". Physiomics is co-authoring the poster with client Numab Therapeutics ("Numab") whose investigational drug NM32 is currently in IND-enabling studies. NM32 is a tri-specific anti-ROR1/CD3/HSA antibody based on Numab's scMATCH3 format which induces T cell-mediated lysis of tumours expressing Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1).
Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection
Just had a look at the VAL board. They seem uber positive about the presentation from Suzy Dilly ( i know we/ they have to be positive ) but we all know what PYC gets if VAL201 does the biz! Correct me if i am wrong, $6m in payments which nearly 3 x our mkt cap?
https://twitter.com/Physiomics/status/1589915657134837760?s=20&t=Z0pGSqURszLA_5ud4UimDQ
Looks like PYC have found some cash behind that there sofa! Now sponsoring partner at https://www.hub-xchange.com/immuno-oncology-xchange-europe-2022/#anchor1 I hope this extras marketing etc is worth it........
Thanks for the links guys - seems a pretty high powered event even if a little expensive? Looks like we're playing with the big boys at last which can only be good.
Tweet site for SITC22
https://twitter.com/hashtag/SITC22?src=hash
https://www.conferenceharvester.com/floorplan/floorplan.asp?EventKey=PRRIFWGJ you can see who we are next to also.
Layout of booths page 4, PYC at booth 236.
https://higherlogicdownload.s3.amazonaws.com/SITCANCER/b4133eb1-990b-40ff-b51e-def6e5968513/UploadedImages/SITC_2022_Exhibitor_Prospectus.pdf
Debs, tar for the prompt. Maybe you can usher those that you mentioned on the SCLP board to come here and have a look? I dont want to particularly gate crash that board and have the possible wrath of SCLP's writers think i am cross ramping!
People like Kidlington, Truro and Ralph know alot about this company
I will look up the results and follow up with more research. I note this is one you follow / invest in and seem happy to do so.
DEBs
Imho one of only a handful of Aim stocks that
growing revenues last 4yrs near profit to profit they have cash runway cash for 3yrs+ and operate in a non discretionary oncology market and are
only AIM listed company that can do its computer modelling for drug company cancer drugs
Hi Debs
I am invested in sclp and they share the same oncology focus BUT PYC are a software/service company which HELP companies like sclp to develop their phase 3 to phase 1 drug development programmes
Probably worth seeing the latest PYC results if that helps
You could ask 'burble' and (Dr) Crumbs/ or to review the data in kidlingtons latest post on the sclp chat board and they should give a sensible view of how things are progressing with PYC and what the prospects are and that should give an idea of its investability. I have been following for quite a while but not invested (yet!) as I am not fully understanding the potential science. So for me I need a second opinion!
Great article L Got the FDA top man in the article who also is in charge of this https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus
Bicycle Therapeutics have also mentioned Project Ootimus for the 1st time i believe: https://investors.bicycletherapeutics.com/static-files/e14b6d6c-9a82-4355-b35a-a795ada69cad